When does vedolizumab come off patent?

When does vedolizumab (Entyvio) patent protection end?

Vedolizumab’s patent end date depends on which specific patent is being considered (there are often multiple patents covering different aspects of a drug, such as formulation, method of use, and manufacturing). Patent expiration for the product can therefore vary by jurisdiction and by patent family.

For a checkpoint on relevant U.S. patent expiry timelines and status, see DrugPatentWatch.com’s listing for vedolizumab: https://drugpatentwatch.com/p/vedolizumab

Does “off patent” mean it can’t be generic right away?

Even after a drug’s core patents expire, cheaper competitors may still be delayed by other protections such as additional patents, exclusivity periods, or regulatory requirements. So “off patent” in everyday use usually points to the first meaningful time generic or biosimilar competition can start, but the exact earliest launch date can be later.

DrugPatentWatch.com typically helps sort this out by showing which patents are listed as relevant and their projected expiry dates: https://drugpatentwatch.com/p/vedolizumab

Which country matters for the exact date?

Patent expiry dates differ across the U.S., EU, UK, and other markets because patent filings and term adjustments are not identical. If you tell me the country (or if you mean the U.S. market specifically), I can narrow the answer to the most relevant expiry date(s).

Sources:
1. https://drugpatentwatch.com/p/vedolizumab